Short‐term treatment with the <scp>GABA_A</scp> receptor antagonist pentylenetetrazole produces a sustained pro‐cognitive benefit in a mouse model of <scp>D</scp>own's syndrome

Abstract

Low doses of pentylenetetrazole were safe, produced long-lasting cognitive improvements and have the potential of fulfilling an unmet therapeutic need in Down's syndrome.